Turning Point Therapeutics (NASDAQ:TPTX) Announces Quarterly Earnings Results
Turning Point Therapeutics (NASDAQ:TPTX) Announces Quarterly Earnings Results
Turning Point Therapeutics (NASDAQ:TPTX – Get Rating) announced its quarterly earnings data on Monday. The company reported ($2.48) earnings per share for the quarter, missing the consensus estimate of ($1.70) by ($0.78), Briefing.com reports. The business had revenue of $0.12 million during the quarter, compared to analysts' expectations of $2.27 million. During the same period in the prior year, the firm earned ($1.14) EPS. The business's revenue was down 97.7% on a year-over-year basis.
Turning Point Therapeutics(纳斯达克股票代码:TPTX —(获取评级)周一公布了其季度收益数据。Briefing.com报告称,该公司公布的本季度每股收益(2.48美元),比市场普遍预期的(1.70美元)(0.78美元)低于(0.78美元)。该业务在本季度收入为12万美元,而分析师的预期为227万美元。去年同期,该公司的每股收益(1.14美元)。该业务的收入同比下降97.7%。
Turning Point Therapeutics Stock Up 0.1 %
转折点疗法股票上涨0.1%
Turning Point Therapeutics stock opened at $75.06 on Tuesday. Turning Point Therapeutics has a one year low of $23.77 and a one year high of $82.20. The business's fifty day moving average is $72.49 and its 200 day moving average is $45.76.
Turning Point Therapeutics股票周二开盘报75.06美元。Turning Point Therapeutics的一年低点为23.77美元,一年高点为82.20美元。该公司的五十天移动平均线为72.49美元,其200天移动平均线为45.76美元。
Wall Street Analyst Weigh In
华尔街分析师权衡一下
Several brokerages have weighed in on TPTX. The Goldman Sachs Group lowered their price objective on Turning Point Therapeutics from $143.00 to $116.00 and set a "buy" rating for the company in a research report on Tuesday, May 24th. SVB Leerink downgraded Turning Point Therapeutics from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $101.00 to $76.00 in a report on Monday, June 13th. Wells Fargo & Company downgraded Turning Point Therapeutics from an "overweight" rating to an "equal weight" rating and set a $76.00 target price for the company. in a report on Friday, June 3rd. Cowen downgraded Turning Point Therapeutics from an "outperform" rating to a "market perform" rating in a report on Monday, June 6th. Finally, Wedbush cut Turning Point Therapeutics from an "outperform" rating to a "neutral" rating and upped their price target for the stock from $61.00 to $76.00 in a research note on Friday, June 3rd. Nine research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $78.22.
几家经纪商对TPTX进行了权衡。高盛集团在5月24日星期二的一份研究报告中将Turning Point Therapeutics的目标股价从143.00美元下调至116.00美元,并对该公司设定了 “买入” 评级。SVB Leerink在6月13日星期一的一份报告中将Turning Point Therapeutics的评级从 “跑赢大盘” 下调至 “市场表现”,并将该公司的目标价格从101.00美元下调至76.00美元。富国银行在6月3日星期五的一份报告中将Turning Point Therapeutics的评级从 “增持” 下调至 “同等权重”,并将该公司的目标股价定为76.00美元。考恩在6月6日星期一的一份报告中将Turning Point Therapeutics的评级从 “跑赢大盘” 的评级下调至 “市场表现”。最后,Wedbush在6月3日星期五的一份研究报告中将Turning Point Therapeutics的评级从 “跑赢大盘” 下调至 “中性”,并将该股的目标股价从61.00美元上调至76.00美元。九位研究分析师对该股进行了持仓评级,三位给出了该公司的买入评级。根据MarketBeat.com的数据,该公司目前的共识评级为 “持有”,共识目标股价为78.22美元。
Insider Activity at Turning Point Therapeutics
转折点疗法的内部活动
Institutional Inflows and Outflows
机构流入和流出
Institutional investors and hedge funds have recently bought and sold shares of the company. Captrust Financial Advisors boosted its position in Turning Point Therapeutics by 176.5% in the first quarter. Captrust Financial Advisors now owns 1,045 shares of the company's stock worth $28,000 after purchasing an additional 667 shares during the last quarter. US Bancorp DE boosted its position in Turning Point Therapeutics by 139.6% in the first quarter. US Bancorp DE now owns 1,143 shares of the company's stock worth $31,000 after purchasing an additional 666 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in shares of Turning Point Therapeutics during the 1st quarter valued at about $96,000. PNC Financial Services Group Inc. lifted its position in shares of Turning Point Therapeutics by 11.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 8,546 shares of the company's stock valued at $230,000 after buying an additional 888 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Turning Point Therapeutics during the 1st quarter valued at about $237,000. 90.33% of the stock is owned by hedge funds and other institutional investors.
机构投资者和对冲基金最近买入和卖出了该公司的股票。Captrust Financial Advisors在第一季度将其在转折点疗法的头寸提高了176.5%。Captrust Financial Advisors在上个季度又购买了667股股票后,现在拥有该公司1,045股股票,价值28,000美元。美国Bancorp DE在第一季度将其在Turning Point Therapeutics中的地位提高了139.6%。美国Bancorp DE在上个季度又购买了666股股票后,现在拥有该公司1,143股股票,价值31,000美元。Point72 Hong Kong Ltd在第一季度购买了Turning Point Therapeutics的新头寸,价值约96,000美元。PNC金融服务集团公司在第一季度将其在Turning Point Therapeutics的股票持仓上调了11.6%。PNC金融服务集团公司在上个季度又购买了888股股票后,现在拥有该公司8,546股股票,价值23万美元。最后,Virtu Financial LLC在第一季度购买了Turning Point Therapeutics的新头寸,价值约23.7万美元。该股票的90.33%由对冲基金和其他机构投资者持有。
Turning Point Therapeutics Company Profile
转折点疗法公司简介
(Get Rating)
(获取评级)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Turning Point Therapeutics, Inc是一家处于临床阶段的精准肿瘤生物制药公司,致力于设计和开发针对癌症遗传驱动因素的疗法。它开发了一系列酪氨酸激酶抑制剂(TKI),靶向未接受过TKI和TKI预治疗的患者中癌症的遗传驱动因素。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- Home Depot, Lowe's On Track To Grow 2022 Earnings
- Could Smaller be Better for Investors in Norwegian Cruise Lines?
- Walmart Or Target: Which Is The Stronger Stock?
- MarketBeat Podcast: Investing in What You Know Has Changed
- Can Etsy Continue to Thrive After the Pandemic?
- 免费获取 StockNews.com 关于 Turning Point Therapeutics (TPTX) 的研究报告
- 家得宝、劳氏有望增长 2022 年的收益
- 对于挪威邮轮公司的投资者来说,规模越小越好吗?
- 沃尔玛还是塔吉特:哪只股票更强?
- MarketBeat 播客:投资你所知道的已经发生了变化
- 疫情过后,Etsy能否继续蓬勃发展?
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收Turning Point Therapeutics日报的新闻和评级——在下方输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收Turning Point Therapeutics及相关公司最新新闻的简明每日摘要和分析师的评级。
译文内容由第三方软件翻译。